S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
Public ClinicalTrials.gov record NCT00121186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Nonmyeloablative Allogeneic Stem Cell Transplantation For Relapsed Hodgkin's or Non-Hodgkin's Lymphoma After Autologous Transplantation ( A BMT Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and methotrexate after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving fludarabine together with melphalan followed by tacrolimus and methotrexate works in treating patients who are undergoing a donor stem cell transplant for relapsed lymphoma.
Study identification
- NCT ID
- NCT00121186
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 1 participant
Conditions and interventions
Conditions
Interventions
- fludarabine phosphate Drug
- melphalan Drug
- methotrexate Drug
- tacrolimus Drug
- allogeneic bone marrow transplantation Procedure
- peripheral blood stem cell transplantation Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2005 (Type not available)
- Primary completion
- Jan 2008 (Actual)
- Completion
- Dec 2011 (Actual)
- Last update posted
- Apr 3, 2012
2005 – 2011
United States locations
- U.S. sites
- 33
- U.S. states
- 5
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cardinal Bernardin Cancer Center at Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| St. Francis Hospital and Health Centers - Beech Grove Campus | Beech Grove | Indiana | 46107 | — |
| Reid Hospital & Health Care Services, Incorporated | Richmond | Indiana | 47374 | — |
| Cancer Center of Kansas, PA - Chanute | Chanute | Kansas | 66720 | — |
| Cancer Center of Kansas, PA - Dodge City | Dodge City | Kansas | 67801 | — |
| Cancer Center of Kansas, PA - El Dorado | El Dorado | Kansas | 67042 | — |
| Cancer Center of Kansas, PA - Kingman | Kingman | Kansas | 67068 | — |
| Southwest Medical Center | Liberal | Kansas | 67901 | — |
| Cancer Center of Kansas, PA - Newton | Newton | Kansas | 67114 | — |
| Cancer Center of Kansas, PA - Parsons | Parsons | Kansas | 67357 | — |
| Cancer Center of Kansas, PA - Pratt | Pratt | Kansas | 67124 | — |
| Cancer Center of Kansas, PA - Salina | Salina | Kansas | 67042 | — |
| Cancer Center of Kansas, PA - Wellington | Wellington | Kansas | 67152 | — |
| Associates in Womens Health, PA - North Review | Wichita | Kansas | 67203 | — |
| Cancer Center of Kansas, PA - Medical Arts Tower | Wichita | Kansas | 67208 | — |
| Cancer Center of Kansas, PA - Wichita | Wichita | Kansas | 67214 | — |
| CCOP - Wichita | Wichita | Kansas | 67214 | — |
| Via Christi Cancer Center at Via Christi Regional Medical Center | Wichita | Kansas | 67214 | — |
| Cancer Center of Kansas, PA - Winfield | Winfield | Kansas | 67156 | — |
| Highland Hospital of Rochester | Rochester | New York | 14620 | — |
| Interlakes Oncology/Hematology PC | Rochester | New York | 14623 | — |
| James P. Wilmot Cancer Center at University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Grandview Hospital | Dayton | Ohio | 45405 | — |
| Good Samaritan Hospital | Dayton | Ohio | 45406 | — |
| David L. Rike Cancer Center at Miami Valley Hospital | Dayton | Ohio | 45409 | — |
| Veterans Affairs Medical Center - Dayton | Dayton | Ohio | 45428 | — |
| CCOP - Dayton | Dayton | Ohio | 45429 | — |
| Blanchard Valley Medical Associates | Findlay | Ohio | 45840 | — |
| Charles F. Kettering Memorial Hospital | Kettering | Ohio | 45429 | — |
| Middletown Regional Hospital | Middletown | Ohio | 45044 | — |
| UVMC Cancer Care Center at Upper Valley Medical Center | Troy | Ohio | 45373-1300 | — |
| United States Air Force Medical Center - Wright-Patterson | Wright-Patterson AFB | Ohio | 45433-5529 | — |
| Ruth G. McMillan Cancer Center at Greene Memorial Hospital | Xenia | Ohio | 45385 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00121186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2012 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00121186 live on ClinicalTrials.gov.